KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31

Kiniksa Pharmaceuticals International, plc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026

$79.48+0.89 (+1.13%)

Close on Oct 19, 2026

Community

Notes and questions about Kiniksa Pharmaceuticals International from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Kiniksa Pharmaceuticals International's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KNSA.

Revenue growth58.9% · median 77.1%

Gross margin89.8% · median 94.4%

Operating margin11.9% · median -33.8%

Net margin9.6% · median -30.1%

Advertisement
300 × 250